DocumentsDate added
Original article
MinSong1,Mei-HuaGao1,2,Wei-Huan Huang1,Man-Mei Li1,Hua Li2,Yao-Lan Li1,Xiao-Qi Zhang1*,Wen-Cai Ye1
1 Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou 510632, China
2 Guangdong Institute for Food and Drug Control, Guangzhou 510180, China
Address reprint requests to:
*Xiao-Qi Zhang,
College of Pharmacy, Jinan University, No. 601 West Huangpu Avenue, Guangzhou 510632, China
Article citation: MinSong, Mei-HuaGao, Huang WH, Li MM, Li H, Li YL, et al.Flavonoids from the seeds of Hovenia acerba and their in vitro antiviral activity. J Pharm Biomed Sci 2016;06(06):401–409.Available at www.jpbms.info
ABSTRACT
A new flavonoid, 6″′-acetyl-spinosin (12), together with 14 known flavonoids, were isolated from Hovenia acerba. Their structures were elucidated by extensive spectroscopic methods. The rotamers of four flavonoid C-glycosides 12–15 was investigated for the first time. All the flavonoids were evaluated for their anti-RSV activity by cytopathic effect (CPE) reduction assay. As a result, five flavonoids, 3, 7, 10, 13, and 14, displayed better antiviral effect against three RSV strains. Plaque reduction assay demonstrated that compound 13 mainly inhibited the intracellular replication of RSV. HPLC analysis indicated that the active compounds 3, 7, and 13 had higher contents in the seeds.
KEYWORDS Hovenia acerba, Rhamnaceae, flavonoids, antiviral activity, RSV
REFERENCES
1.Kott V, Barbini L, Cruanes M, Munoz JD, Vivot E, Cruanes, et al. Antiviral activity in Argentine medicinal plants. J Ethnopharmacol.1999;64(1):79–84.
2.Antonelli G, Turriziani O. Antiviral therapy: old and current issues. Int J Antimicrob Agents. 2010;40(2):95–102.
3.Glatthaar Saalmüller B, Rauchhaus U, Rode S, Haunschild J,Saalmüller A. Antiviral activity in vitro of two preparations of the herbal medicinal product sinupret against viruses causing respiratory infections. Phytomedicine. 2011;19(1):1–7.
4.Hyun TK, Eom SH, Yu CY, Roitsch T. Hovenia dulcis – an Asian traditional herb. Planta Med. 2010;76(10):943–949.
5.Chen YL, Carsten S. Rhamnaceae. In: Raven PH, Zhang LB,AI-Shehbaz IA, Turland NJ, Zhu GH, editors. Flora of China. Beijing: Science Press. 2008; p. 117–119.
6.Zhang XQ, Xu FF, Wang L, Huang MY, LiuZ, Zhang DM, et al. Two pairs of new diastereoisomeric flavonolignans from the seeds of Hovenia acerba. Phytochem Lett. 2012;5(2):292–296.
7.Kim DH, Sung NY, Kim JS, Kim JH, Hwang YJ, Lee JW.Alcohol metabolizing and antioxidant activities of complex herbal extracts from medicinal plants. Food Sci Biotechnol.2011;20(5):1337–1345.
8.Xu BJ, Deng YQ, Sung CK. Advances in studies on bioactivity of Hovenia dulcis. Agric Chem Bio. 2004;47(1):1–5.
9.Xu FF, Fan CL, Wang L, Wang GC, Zhang XQ, Ye WC. Chemical constituents from the seeds of Hovenia acerba. J Jinan Univ Nat Sci Med (China). 2011;32(3):304–306.
10.Liang QL, Ding LS. Chemical constituents from the leaves of Hovenia acerba. Chin. Tradit Herbal Drugs (China). 1996;27(7):581–583.
11.Ding LS, Liang QL, Teng YF. Flavone constituents from the seeds of Hovenia acerba. J Pharmaceutical. 1997;32(3):600–602.
12.Yoshikawa M, Murakami T, Ueda T, Yoshizumi S, Ninomiya K,Murakami N, et al. Bioactive constituents of Chinese natural medicines. III. Absolute stereo structures of new dihydroflavonols, hovenitins I, II, and III, isolated from hoveniae semen seufructus, the seed and fruit of Hovenia dulcis THUNB. (Rhamnaceae): inhibitory effect on alcohol-induced muscular relaxation and hepatoprotective activity. Yakugaku Zasshi. 1997;117:108–118.
13.Takahashi H, Li S, Harigaya Y, Onda M. Heterocycles. X XII.Stereoselective synthesis of (+)-aromadendrin trimethyl ether and its enantiomer, and their reduction. Chem Pharm Bull.1988;36(5):1877–1881.
14.Jeon SH, Chun W, Choi YJ, Kwon YS. Cytotoxic constituents from the bark of Salix hulteni. Arch Pharm Res. 2008;31(8):978–982.
15.Huang DW, Chung CP, Kuo YH, Lin YL, Chiang W. Identification of compounds in adlay (Coixlachryma-jobi L. var. ma-yuen Stapf ) seed hull extracts that inhibit lipopolysaccharide-induced inflammation in RAW 264.7 macrophages. J Agric Food Chem. 2009;57(22):10651–10657.
16.Foo LY, Newman R, Waghorn G, McNabb WC, Ulyatt MJ. Proanthocyanidins from Lotus corniculatus. Phytochemistry. 1996;41(2):617–624.
17.Cheng G, Bai YJ, Zhao YY, Tao J, Liu Y, Tu GZ, et al. Flavonoids from Ziziphusjujuba Mill var. spinosa. Tetrahedron. 2000;56(45):8915–8920.
18.Woo WS, Kang SS, Wagner H, Seligmann O, Chari VM. Acylated flavone-C-glycosides from the seeds of Zizyphus jujube.Phytochemistry. 1980;19(12):2791–2793.
19.Ooi LS, Wang H, He Z, Ooi VE. Antiviral activities of purified compounds from Youngia japonica (L). DC (Asteraceae, Compositae). J Ethnopharmacol. 2006;106(2):187–191.
20.Li Y, Ooi LSM, Wang H, But PP, Ooi VE. Antiviral activities of medicinal herbs traditionally used in southern mainland China. Phytother Res. 2004;18(9):718–722.
21.Li YL, Leung KT, Yao FH, Ooi LSM, Ooi VEC. Antiviral flavans from the leaves of Pithecellobium clypearia. J Nat Prod. 2006;69(5):833–835.
22.Ho WS, Xue JY, Sun SS, Ooi VE, Li YL. Antiviral activity of daphnoretin isolated from Wikstroemia indica. Phytother Res. 2010;24(5):657–661.
23.Lewis KC, Maxwell AR, McLean S, Reynolds WF, Enriquez RG.Room-temperature (1H, 13C) and variable-temperature (1H) NMR studies on spinosin. Magn Reson Chem. 2000;38(9):771–774.
24.Li YL, Li KM, Su MX, Leung KT, Chen YW, Zhang YW. Studies on antiviral constituents in stems and leaves of Pithecellibium clypearia. China J Chin Mater Med (China). 2006;31(5):397–400.
25.Shen XR, Zhang DZ. Research advances in plants of Genus Hovenia. Shizhen Guoyi Guoyao (China). 2007;18(6):1351–1355.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: This work was supported by grants from the National Natural Science Foundation (No. 81373935), the Science and Technology Planning Project of Guangdong Province (No. 2013A022100028), and the Administration of Traditional Chinese Medicine of Guangdong Province (No. 20131139).
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Sipra Lenka,Amit Agrawal*,Pratima Mishra
Department of Obstetrics & Gynaecology, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
Address reprint requests to:
*Amit Agrawal, Department of Obstetrics & Gynaeacology, Hi-Tech medical college and hospital, Bhubaneswar, Orissa, India
Article citation: Lenka S, Agrawal A,Mishra P. Oral misoprostol versus intravenous methylergometrine for the prevention of postpartum haemorrhage. J Pharm Biomed Sci 2016;06(06):399–400.Available at www.jpbms.info
ABSTRACT
Background Post partum haemorrhage is one of the most common causes of maternal mortality. Uterine atonicity, trauma to the genital tract, retained product of placenta are common causes of postpartum haemorrhage (PPH), out of these, atonicity contributes to a majority of cases. Many drugs have been used for the contraction of the uterus such as oxytocin, misoprostol and methylergometrine. In this study, the role of IV methylergometrine was compared with oral misoprostol for the prevention of PPH.
Materials and Methods Study of 180 women who received IV methylergometrine or oral misoprostol 600 mcg to prevent post PPH was carried out in the labour room of Hi-Tech Medical College and Hospitals, Bhubaneswar, Odisha, India, between January 2014 and January 2015.
Result In this study oral misoprostol was found to be safe, non invasive and effective method in prevention of PPH specially in low resource setting in India.
Conclusions In this study oral misoprostol was found to be safe, non invasive and effective method in prevention of PPH specially in low resource setting in India.
KEYWORDS postpartum haemorrhage, misoprostol, methylergometrine
REFERENCES
1.Ramanathan G, Arulkumaran S. Postpartum haemorrhage. Curr Obstet Gynaecol. 2006;16(1):6–13.
2.Kane TT, el-Kady AA, Saleh S, Hage M, Stanback J, Potter L. Maternal mortality in Giza, Egypt: magnitude, causes, and prevention. Stud Fam Plann. 1992;23:45–57.
3.Prendiville WJ, Elbourne D, McDonald S. Active versus expectant management in the third stage of labour. Cochrane Database Syst Rev. 2000;3:CD000007.
4.Potts M, Prata N, Walsh J, Grossman A. Parachute approach to evidence based medicine. BMJ. 2006;333:701–703.
5.Hogerzeil HV, Walker GJ. Instability of (methyl) ergometrine in tropical climates: an overview. Eur J Obstet Gynecol Reprod Biol.1996;69:25–29.
6.Hofmeyr GJ, Walraven G, Gülmezoglu AM, Maholwana B, Alfirevic Z, Villar J. Misoprostol to treat postpartum haemorrhage: a systematic review. BJOG. 2005;112:547–553.
7.Sanghvi H. Prevention of postpartum hemorrhage study, West Java, Indonesia. 2004.
8.Mousa HA, Alfirevic Z. Treatment for primary postpartum hemorrhage. Cochrane Database Syst Rev. 2007;1:CD003249 .
9.Caliskan E, Dilbaz B, Meydanli MM, Oztürk N, Narin MA, Haberal A. Oral misoprostol for the third stage of labor: a randomized controlled trial. Obstet Gynecol. 2003;101:921–928.
10.Lalonde A, Daviss BA, Acosta A, Herschderfer K. Postpartum hemorrhage today: ICM/FIGO initiative 2004-2006. Int J Gynecol Obstet. 2006;94:243–53.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Original article:
Xiaoyong Jin1,Zheng Liu2,Baojian Guo1,Gaoxiao Zhang2,Zaijun Zhang2,Lipeng Xu2,Yuqiang Wang2,Yewei Sun2*
1 Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, Jinan University College of Pharmacy,Guangzhou, 510632, China
2 Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, 510632, China
Address reprint requests to
*Yewei Sun, Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, Jinan University College of Pharmacy,Guangzhou, 510632, China
Article citation: Jin X, Liu Z, Guo B,Zhang G, Zhang Z, Xu L, Wang Y, Sun Y. A promising dual-functional neuroprotective derivative of memantine. J Pharm Biomed Sci 2016;06(06):392–398.Available at www.jpbms.info
ABSTRACT
Background Memantine, an open-channel, uncompetitive blocker of NMDA receptors, is a major treatment for moderate-to-severe Alzheimer’s disease. The NMDA receptor activity can also be inhibited allosterically by S-nitrosylation of Cys residues, a redox-mediated chemical reaction.
Aim To enhance the inhibitory effect of memantine on NMDA receptors and its neuroprotective effect. Settings and Design In this study, we designed and synthesized a memantine nitrate compound (MN-2, also known as YQW-035), with the potential for both allosteric and direct uncompetitive blockade. Then, the protective effects of MN-2 were evaluated both in vitro and in vivo.
Results and Conclusions Biological evaluations demonstrated that MN-2 showed a stronger protective effect in cultured neuronal cells and in a rat transient stroke model compared with memantine. The mechanism underlying the action of MN-2 may be attributed to its dual inhibition of NMDA receptors. These results suggested MN-2 has promising potential for treatment of various neurological disorders characterized by overstimulation of NMDA receptors.
KEYWORDS memantine nitrate, neurological disorder, NMDA receptor, S-nitrosylation
REFERENCES
1.Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr. 2000;130:1007–1015.
2.Campos F, Perez-Mato M, Agulla J, Blanco M, Barral D, Almeida A, et al. Glutamate excitoxicity is the key molecular mechanism which is influenced by body temperature during the acute phase of brain stroke. PLoS One. 2012;7(8):e44191.
3.Nguyen D, Alavi MV, Kim KY, Kang T, Scott RT, Noh YH, et al. A new vicious cycle involving glutamate excitotoxicity, oxidative stress and mitochondrial dynamics. Cell Death Dis. 2011;2:e240.
4.Hazell AS. Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. Neurochem Int. 2007;50:941–953.
5.Sattler R, Tymianski M. Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. Mol Neurobiol.2001;24:107–129.
6.Szydlowska K, Tymianski M. Calcium, ischemia and excitotoxicity.Cell Calcium. 2010;47:122–129.
7.Arundine M, Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium.2003;34:325–337.
8.Skaper SD, Facci L, Strijbos PJ. Neuronal protein kinase signaling cascades and excitotoxic cell death. Ann N Y Acad Sci. 2001;939:11–22.
9.Chen H, Lipton SA. Mechanism of memantine block of NMDAactivated channels in rat retinal ganglion cells: uncompetitive antagonism. J Physiol. 1997;499:27–46.
10.Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig NH, Rogers JT, et al. N-Methyl D-Aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s disease, vascular dementia and Parkinson’s disease. Curr Alzheimer Res. 2012;9:746–758.
11.Chen H, Wang Y, Rayudu P, Edgecomb P, Neill J, Segal M, et al.Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience. 1998;86:1121–1132.
12.Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology. 2007;53: 699–723.
13.Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA. 1991;88:6368–6371.
14.Choi YB, Tenneti L, Le DA, Ortiz J, Bai G, Chen HV, et al. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat Neurosci. 2000;3:15–21.
15.Zurakowski D, Vorwerk CK, Gorla M, Kanellopoulos AJ, Chaturvedi N, Grosskreutz CL, et al. Nitrate therapy may retard glaucomatous optic neuropathy, perhaps through modulation of glutamate receptors. Vision Res. 1998;38:1489–1494.
16.Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HSV, Sucher NJ, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature. 1993;364:626–632.
17.Stroke TAIRS. Recommendations for standards regarding preclinical neuroprotective and restorative drug development.Stroke. 1999;30:2752.
18.Chen CJ, Liao SL, Chen WY, Hong JS, Kuo JS. Cerebral ischemia/reperfusion injury in rat brain: effects of naloxone. Neuroreport.2001;12:1245–1249.
19.Woodruff TM, Thundyil J, Tang SC, Sobey CG, Taylor SM, Arumugam TV. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol Neurodegener.2011;6:11.
20.Jiang Q, Jiang Y, Wang J, Qin J, Wu X. An improved method for primary culture of rat cortical neuron and cell identification.Beijing Da Xue Xue Bao. 2009;41:212–216.
21.Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84–91.
22.Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol. 2006;6:61–67.
23.Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C,Sharp FR. A semiautomated method for measuring braininfarct volume. J Cereb Blood Flow Metab. 1990;10:290–293.
24.Maier CM, Cheng ML, Lee JE, Yenari MA, Steinberg GK. Optimal depth and duration of mild hypothermia in a focal model of transient cerebral ischemia effects on neurologic outcome, infarct size, apoptosis and inflammation. Stroke. 1998;29:2171–2180.
ORIGINAL ARTICLE
Min Yang,S-Shan Zhou,Y-Zhen Zhang,Guo-hua Cheng*
School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, China, P.C. 510632
Address reprint requests to
*Guo-hua Cheng, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, China, P.C. 510632
Article citation: Yang M, Zhou SS, Zhang YZ, Cheng GH. A systematic review for the contraceptive efficacy and safety of compound left acetylene progesterone tablets. J Pharm Biomed Sci 2016;06(06):381–386. Available at www.jpbms.info
ABSTRACT
Background and Objectives There is limited information on the efficacy and safety of compound left acetylene progesterone tablets (LNG/EE 100/20 μg) in contraception. To evaluate the efficacy and safety of LNG/EE 100/20 μg for contraception.
Method We searched the medical databases including Pubmed, Web of science, EMbase and Cochrane library through computer; extracted and evaluated the data then performed the meta-analysis by using Review Manager 5.3 software.
Result A total of seven randomised controlled trials including 1786 subjects were recruited for meta-analysis. Compared with other compound oral contraceptives, LNG/EE 100/20 μg showed no significant differences in contraception efficacy [OR = 1.08, 95% CI (0.29, 4.04), P = 0.91] and safety [OR = 0.99, 95% CI (0.81, 1.21), P = 0.92]; however, it is better than the other compound oral contraceptives on cycle control efficacy of short cycle [OR = 1.75, 95% CI (1.28, 2.38), P = 0.0004].
Conclusion LNG/EE 100/20 μg were better than the other compound oral contraceptives on cycle control of short cycle, and showed no significant differences in the efficacy and safety.
KEYWORDS compound left acetylene progesterone tablets; contraception; efficacy; safety; meta-analysis
REFERENCES
1.Huang ZR, Wu SC. Development and application of combined oral contraceptives. J Int Reprod Health Fam Plan. 2009;28(3):139–144.
2.Cheng HL, Gao ES. Research report for oral contraceptives and contraceptives. J Reprod Contracept. 2006;26(1):31–46.
3.Mishell DR Jr. Oral contraception: past, present, and future perspectives.Int J Fertil. 1991;36(1):7–18.
4.Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol. 1992;21(1):48–52.
5.Sartoretto JN, Ortega-Recio JC. Clinical evaluation of a low dosage estrogen-progesterone association (100 μg of d-norgestrel and 20 μg of ethinyl estradiol). Rev Bras Clin Ther. 1974;3(1):399–404.
6.Hartling L, Ospina M, Liang YY, Dryden DM, Hooton N, Seida JK, et al. Risk of bias versus quality assessment of randomised controlled trials: cross sectional study. BMJ. 2009;339:b4012.
7.Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
8.Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193–206.
9.Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
10.Reisman H, Martin D, Michael J. A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 μg levonorgestrel with 20 μg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol. Am J Obstet Gynecol. 1999;181:45–52.
11.Endrikat J, Hite R, Bannemerschult R, Gerlinger C, Schmidt W. Multilateral, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 μg ethinylestradiol/100 μg levonorgestrel and 20 μg ethinylestradiol/500 μg norethisterone. Contraception.2001;64:3–10.
12.Jespersen J, Endrikat J, Dűsterberg B, Schmidt W, Gerlinger C, Wessel J, et al. A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 μg of ethinylestradiol and 100 μg of levonorgestrel with 30 μg of ethinylestradiol and 100 μg of levonorgestrel. Contraception.2005;72:98–104.
13.Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception. 2006;74:220–223.
14.Seidman L, Kroll R, Howard B, Ricciotti N, Hsieh J, Weiss H. Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial. Contraception. 2015;91:495–502.
15.DelConte A, Loffer F, Grubb GS. Cycle control with oral contraceptivescontaining 20 μg of ethinyl estradiol: a multicenter, randomized comparison of levonorgestrel/ethinylestradiol (100μg/20 μg) and norethindrone/ethinylestradiol (1000 μg/20 μg).Contraception. 1999;59:187–193.
16.Endrikat J, Klipping C, Cronin M, Gerlinger C, Ruebig A, Schmidt W, et al. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception. 2002;65:215–221.
17.Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low-and lower-dose oral contraceptives: a randomized trial of 20 μg and 35 μg estrogen preparations. Contraception. 1999;60:321–329.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Research article
J. D. Andhale*,R. N. Misra,N. R. Gandham,K. M. Angadi,S. V. Jadhav,C. R. Vyawahare,M. Pawar,S. Hatolkar
Dr. D. Y. Patil Medical College, Hospital and Research Centre (D. Y. Patil Vidyapeeth, Pune), Pimpri, Pune, 411018, India
Address reprint requests to
*Mr. J. D. Andhale, [Ph. D. Scholar],
Department of Microbiology, Dr. D. Y. Patil Medical College, Hospital and Research Centre (D. Y. Patil Vidyapeeth, Pune), Pimpri,Pune, 411018, India
Article citation: Andhale JD, Misra RN, Gandham NR, Angadi KM, Jadhav SV, Vyawahare CR et al. Incidence of Pseudomonas aeruginisa with special reference to drug resistance and biofilm formation from clinical samples in tertiary care hospital. J Pharm Biomed Sci 2016;06(06):387–391. Available at www.jpbms.info
Background Pseudomonas aeruginosa (P. aeruginosa ) is an aerobic, gram negative, motile rod and possesses a variety of virulence factors. Antimicrobial resistance is an innate feature of bacterial biofilms.
Objectives Determination of prevalence, antibiotic susceptibility and biofilm production of P. aeruginosa isolates from clinical samples.
Materials and Methods A prospective study was carried out from the period of June 2014 to December 2014 in Microbiology Department, Dr. D. Y. Patil Medical College, Pune. The study included a total of 300 various clinical samples received in the department of Microbiology from different wards for routine culture and sensitivity test. The samples were processed and isolates were identified by standard protocol. All isolates were tested for phenotypic detection of biofilm formation and antibiotic resistance pattern.
Results Out of 300 clinical samples, 30 samples were positive for P. aeruginosa (10%). Maximum of 19 isolates were from pus/wound swab (63.33%) followed by urine 5 (20%). 23 (76.66%) were from males and 7 (23.33%) were from females. Maximum prevalence belonged to the age group of 41–60 years of age 14 (46.66%), followed by patients of 60–80 years of age 8 (26.66%). A total of 13 of the 30 isolates (43.33%) showed biofilm
production. 66.66% (10/15) of multiple antibiotic resistant isolates showed biofilm production. P. aeruginosa was highly resistant to ceftazidime 50% and least resistant to imipenem 10%.
Conclusion The results confirmed P. aeruginosa is a common pathogen isolated from various clinical samples of patients. In this study, the antibiotic resistance was significantly higher among biofilm-producing P. aeruginosa than non-producer. Imipenem was found to be the most effective antimicrobial agent. Use of ceftazidime should be restricted as it found least effective. To avoid rapid emergence of drug resistant strains, periodic testing of biofilm formation and antibiotic sensitivity should be carried out to detect the resistance trends. As this is a hospital-based epidemiological data, present study will help for implementation of better patient management and infection control strategies.
KEYWORDS P. aeruginosa, biofilm, Imipenem, ceftazidime
REFERENCES
1.Pathmanathan SG, Samat NA, Mohamed R. Antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa from a Malaysian hospital. Malays J Med Sci. 2009;16(2):28–33.
2.Deplano A, Denis O, Poirel L, Hocquet D, Nonhoff C, Byl B, et al.Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa. J Clin Microbiol. 2005;43:1198–1204.
3.Stover CK, Pham XQ, Erwin AL, et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.Nature. 2000;406:959–964.
4.Engel J, Balachandran P. Role of Pseudomonas aeruginosa type III effectors in disease. Curr Opin Microbiol. 2009;12:61–66.
5.Alous V, Navon-Venezia S, Seigman-Igra Y, Carmeli Y. Multidrugresistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50(1):43–8.
6.Gad GF, EI-Domany RA, Zaki S, Ashour HM. Characterization of Pseudomonas aeruginosa isolated from clinical and environmental samples in Minia, Egypt: prevalence, antibiogram and resistance mechanisms. J Antimicrob Chemother. 2007;60(5):1010–7.
7.Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35:322–332.
8.Dunne WM Jr. Bacterial adhesion: seen any good biofilms lately? Clin Microbiol Rev. 2002;15:155–660.
9.Potera C. Forging a link between biofilms and disease. Science.1999;283:1837–1838.
10.Rajamohan G, Srinivasan VB, Gebreyes WA: Biocide-tolerant multidrug-resistant Acinetobacter baumannii clinical strains are associated with higher biofilm formation. J Hosp Infect. 2009;73:287–289.
11.Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167–93.
12.Sanchez CJ Jr, Mende K, Beckius ML, Akers KS, Romano DR,Wenke JC, et al. Biofilm formation by clinical isolates and the implications in chronic infections. BMC Infect Dis. 2013;13:47.
13.Rao RS, Karthika RU, Singh SP, Shashikala P, Kanungo R, Jayachandran S, et al. Correlation between biofilm production and multiple drug resistance in imipenem resistant clinical isolates of Acinetobacter baumanii. Indian J Med Microbiol.2008;26:333–7.
14.Bongo G, Granchino Y, Amicosante L, et al. Mechanisms of beta-actam resistance amongst Pseudomonas aeruginosa isolated in an Italian survey. J Antimicrob Chemother. 1998;42:697–702.
15.Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 22nd informational supplement: M100-S22. Wayne: CLSI; 2012.
16.Christensen GD, Simpson WA, Bisno AL, Beachey EH. Adherence of slime-producing strains of Staphylococcus epidermidis to smooth surfaces. Infect Immun. 1982;37(1):318–326.
17.Dash M, Padhi S, Narasimham MV, Pattnaik S. Antimicrobial resistance pattern of Pseudomonas aeruginosa isolates from various clinical samples in a tertiary care hospital, South Odisha, India. Saudi J Health Sci. 2014;3:15–9.
18.Siham SAS, Hameed BH. Antibiotic resistant of Pseudomonas aeruginosa isolated from different clinical specimens. Kirkuk Univ J Sci Stud. 2014;9(2):15–28.
19.Rajat RM, Ninama GL, Mistry K, Parmar R, Patel K, Vegad MM.Antibiotic resistance pattern in Pseudomonas aeruginosa species isolated at a tertiary care Hospital, Ahmedabad. Nat J Med Res.2012;2:156–9.
20.Javiya VA, Ghatak SB, Patel KR, Patel JA. Antibiotic susceptibility patterns of Pseudomonas aeruginosa at a tertiary care hospital in Gujarat, India. Indian J Pharmacol. 2008;40:230–4.
21.Srinivas B, Devi DI, Rao BN. A prospective study of Pseudomonas aeruginosa and its antibiogram in a teaching hospital of rural setup. J Pharm Biomed Sci. 2012;22:1–4.
22.Pathi B, Mishra SN, Panigrahi K, Poddar N, Lenka P, Mallick B. Prevalence and antibiogram pattern of Pseudomonas aeruginosa in a tertiary care hospital from Odisha, India. Transworld Med J. 2013;1(3):77–80.
23.Ahmed SM, Jakribettu RP, Kottakutty S, Arya B, Shakir VPA.An emerging multi-drug resistant pathogen in a tertiary care centre in North Kerala. Ann Biol Res. 2012;3(6):2794–99.
24.Raakhee T, Rao US. Prevalence and resistance pattern of Pseudomonas strains isolated from ICU patients. Int J Curr Microbiol Appl Sci. 2014;3(3):527–534.
25.Gurung J, Khyriem AB, Banik A, Lyngdoh WV, Choudhury B, Bhattacharyya P. Association of biofilm production with multidrug resistance among clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa from intensive care unit. Indian J Crit care Med. 2013:17:214–8.
26.Dardi CK, Wankhede SV. A study of biofilm formation and metallo-β-lactamase in Pseudomonas aruginosa in a tertiary care rural hospital. Int J Sci Res Pub. 2013;3.
27.Arora D, Jindal N, Romit KR. Emerging antibiotic resistance in Pseudomonas: a challenge. Int J Pharm Pharm Sci. 2011;3(2):82–84.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Ethical approval: The study was approved by the institutional ethics committee.
Acknowledgments: The authors would like to extend their thanks to the management and the head of the institute for giving opportunity to conduct research. They are also thankful to members of the D. Y. Patil Vidyapeeth for their help and support. The authors acknowledge the assistance provided by Neelam Sing (Senior Technician) at different stages of this study.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the study.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.